Apollo Endosurgery (NASDAQ:APEN) has been given a $10.00 price target by research analysts at Roth Capital in a research report issued on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price objective suggests a potential upside of 66.67% from the stock’s previous close.
Several other equities analysts have also issued reports on APEN. ValuEngine raised Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a report on Wednesday. Northland Securities reaffirmed a “buy” rating on shares of Apollo Endosurgery in a report on Friday, October 27th. Finally, Zacks Investment Research lowered Apollo Endosurgery from a “buy” rating to a “hold” rating in a report on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $9.44.
Apollo Endosurgery (APEN) opened at $6.00 on Thursday. The stock has a market capitalization of $100.63, a P/E ratio of -0.16 and a beta of 0.44. The company has a quick ratio of 2.00, a current ratio of 2.54 and a debt-to-equity ratio of 0.58. Apollo Endosurgery has a twelve month low of $3.55 and a twelve month high of $19.00.
Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new position in shares of Apollo Endosurgery in the third quarter worth $119,000. Woodmont Investment Counsel LLC bought a new position in shares of Apollo Endosurgery in the third quarter worth $220,000. Russell Investments Group Ltd. bought a new position in shares of Apollo Endosurgery in the third quarter worth $1,288,000. King Luther Capital Management Corp bought a new position in shares of Apollo Endosurgery in the third quarter worth $2,567,000. Finally, Stonepine Capital Management LLC bought a new position in shares of Apollo Endosurgery in the third quarter worth $11,067,000. 23.67% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Apollo Endosurgery (APEN) PT Set at $10.00 by Roth Capital” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2018/01/06/apollo-endosurgery-apen-pt-set-at-10-00-by-roth-capital.html.
About Apollo Endosurgery
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.